Animascope is an R&D contract services company specializing in multi-modality, non-invasive biomedical imaging for therapeutic areas including oncology and cardiology. The company offers comprehensive, cost-effective, and time-efficient turnkey services that reduce animal usage and enhance predictability in clinical outcomes, with operations in several French cities since 2003. Animascope utilizes a range of imaging techniques and collaborates with experts to optimize drug discovery and development processes.

1. TURNKEY SERVICESone-stop shopmolecular imagingdiscovery imagingpreclinical imagingAntonio 07Nov09www.animascope.eu

2. EXECUTIVE SUMMARYAnimascope is an R&D contract services company that specialises in multi-modality non-invasive biomedical imaging in vivofor discovery and preclinical exploratory research on animalsin several therapeutic areas, onco, cardio, bones etc.In vivo visualisation oftissues, functions and dysfunctions, whole-body Cost-effective and time-effective approachStreamline discovery and preclinical studiesIncrease predictability of clinical outcomesReduce experimental artifacts, Refine studies on animal models, Reduce the animal usage from 100% down to 20-30%To be earlier in the marketAntonio 07Nov09

3. ANIMASCOPE INTEGRATED KNOWLEDGETECHNOLOGYprovidersBIOMARKERSprovidersSOFTWAREprovidersFULL STUDYMANAGEMENTANIMAL MODELSprovidersMANAGEMENTexpertiseAntonio 07Nov09THERAPEUTICexpertise

4. COMPETITIVE ADVANTAGESYears of Experience

5. Transversal Expertise, Integrated Knowledge

6. Turnkey Services, One-Stop Shop

7. Multi-modality Techniques

8. International Recognition

9. In Business since 2003 (700 k EUR sales)

10. First in the Market (2008, EU)

11. Operations in Geneva, Lyon, St. Etienne (France)Antonio 07Nov09

12. NON-INVASIVE IN VIVO IMAGINGWhole-body 3D detection of tissues and moleculesreached unprecedented sensitivity and speedproviding exclusive pathophysiology and anatomy readoutsBridges the gap between preclinical and clinical R&DImaging means MetricsQuantitative, Precise, PredictiveReduces experimental Artifacts (in vivo)Longitudinal Studies -Reduce Animal Usage (minus 70-80%)Reduction and Refinement of animal works areCost and Time-effective on R&DAntonio 07Nov09

13. IMAGING IN DRUG DISCOVERY AND DEVELOPMENTAntonio 07Nov09

14. IMAGING IN DRUG DISCOVERY AND DEVELOPMENTStudies on Drug Delivery and Liberation (drug to target)Efficacy, Safety, Pathology (desiderable and undesirable effects)Ligand-Target interaction (receptors, enzymes, transporters) including Dose Occupancy relationshipsDynamic Biodistribution and KineticsImaging is suitable for ADME studies of NCE and BiologicsIn vivo studies of peptides, antibodies, cell therapies, nanoparticles, nutraceuticals, materials. Studies of pathophysiology, phenotyping, translational research and model validation studiesAntonio 07Nov09

15. REDUCTION OF ANIMAL USAGETIME COURSE – HISTOPATH / AUTORADGroupsABCDAntonio 07Nov09E12345

16. REDUCTION OF ANIMAL USAGELONGITUDINAL STUDY – IN VIVO IMAGING Reduced Number of animals (down to 20%)

17. Reduced Variability: each is a self control

18. Reduced Artifacts: all are alive

19. Reduced Time for each experiment

20. Reduced Cost for the study

21. Reduced Ethical impactAntonio 07Nov09E12345

22. X-RAY COMPUTED TOMOGRAPHY (CT)CT is well-suited for in vivo 3D analysis of Bone tissuesat a high level of spatial resolution (10 µm).Using specific contrast media, can be used for anatomical and functional analysis ofSoft tissuesCT provides 3D anatomical images with spatial resolution 10-100 µmAntonio 07Nov09

23. MAGNETIC RESONANCE IMAGING (MRI)MRI provides anatomical, functional and metabolic images with or without the use of specific contrast mediaIt is particularly suited for soft tissuessuch as brain and heartRoutinely, spatial resolution varies around 100 µm in 3DAntonio 07Nov09

24. NUCLEAR IMAGINGPOSITRON EMISSION TOMOGRAPHY (PET)SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) An increasing number of radio-tracers are available (positron or gamma-emitters), permitting 3D whole-body evaluationof biochemical pathways, ligand-receptor binding, antibody-antigen distribution and energy metabolism(molecular imaging)Spatial resolution is close to 1 mmAntonio 07Nov09

25. OPTICAL IMAGINGUsing fluorescent and bioluminescent probes, in vivo whole-body imaging provides images related to specific biochemical pathways (molecular imaging)It is also well suited for biodistribution analysis, cell trafficking and functional genomics studiesThe number of markers available is rapidly increasing while 3D technologies for Quantitative Tomography are emerging as the golden standard in this fieldAntonio 07Nov09

26. ULTRASONOGRAPHY (US)EchographyMany applications, including development and reproductive medicine studiesProvides 2D anatomical informationCombined with Doppler analysis allows evaluation of functional parameters, particularly in the cardiovascular and muscular fieldsThe spatial resolution rangesfrom 30 to 100 µmAntonio 07Nov09

27. MULTI-MODALITY IMAGINGX-ray CT and PETDual ModalityFunction & AnatomyOptimise and Customise Each ProtocolMulti-modality imaging allows to collect, combine and compare multiple readouts within the same anatomical structure and experimental frameAnimascope utilizes a wide set of non-invasive technologies, all the main imaging techniquesX-Ray CT, MRI, PET/SPECT, US, OPTICAntonio 07Nov09Courtesy of Siemens

28. THERAPEUTIC AREASONCOLOGY – BONES – CARDIOLOGYMoreover Cardiovascular

29. Cell Therapy, Gene Therapy

30. Development, Reproduction (Reprotox, Teratology)

31. Gastrointestinal

32. GenitoUrinary, Nephrology

33. Immunization, Vaccination

34. MusculoSkeletal

35. Metabolism, Nutrition

36. Neurobiology, CNSAntonio 07Nov09

37. INDUSTRY SEGMENTSImaging is utilized in viarious industry segments RED BIOTECHNOLOGY

38. BIOLOGICS, BIOPHARMACEUTICALS

39. Nanotechnology, Tracers, Biomarkers, Contrast Agents

40. Nutraceuticals, Functional Food, Dietary Supplements

41. Phytopharmaceuticals

42. Agrichemicals, Environment and Chemistry(risk assessment)

43. Biomaterials, Bio-compatible materials, other MaterialsAntonio 07Nov09

44. TURNKEY SERVICESOur turnkey services are based on integrated services and multi-disciplinary skills. Customisable services and full studies are available depending on customer needs. Every project is tailored to optimize outcomes and readoutsPROTOCOL DESIGNDefinition of biological parameters to be measuredChoice of imaging modalities, contrast agents, tracers, biomarkersDesign of image processing workflowSTUDY MANAGEMENTModel Pre-conditioningImage acquisitionRecording and traceabilityIMAGE PROCESSINGImage handling and pre-processingData analysisREPORTINGTechnical reportingBiomedical reporting Antonio 07Nov09

45. ONE-STOP SHOP SERVICESWe are committed to offer a global range of preclinical imaging services to our customers. Additional services are: ANIMAL MODEL SELECTION AND SOURCING

46. PRE-CONDITIONING OF ANIMAL MODELS

47. SOFTWARE DEVELOPMENT

48. CONSULTANCY

49. TRAINING Antonio 07Nov09

50. ANIMAL MODELSSeveral models can be utilised, disease models and normal controls, including xenografts, mutants, pre-conditioned animalsSeveral species can be used, such as mice, rats, guinea-pigs, microcebus, rabbits, and larger speciesAntonio 07Nov09

51. ANIMASCOPE COLLABORATIONSAnimascope collaborates with companies specialised in radiotracers, biodistribution and in regulatory affairs. Moreover, Animascope offers direct access to a range of established ANIMAL MODELS and related screenings, including: Subcutaneous cancer xenografts

52. Orthotopic cancer xenografts

53. MetastasisOther models:Angiogenesis, Diabetes, CNS disordersArthritis, Autoimmune EncephalomyelitisInflammatory Bowel DiseaseAntonio 07Nov09

54. REGULATORY AFFAIRS CONSULTINGInternational ServicesA full range of regulatory and development servicesis provided, including:Regulatory Strategy Development

55. Clinical Trial and IND preparation

56. MAA and NDA preparation in electronic Common Technical Dossier formatDocument management implementation

57. Toxicology, CMC, Drug Safety support services

58. US Agent servicesAntonio 07Nov09www.drugstomarket.com

59. REGULATORY AFFAIRS CONSULTINGOverview of Therapeutic Agents Quality Assurance including audits (through partners)

60. Drugs (small molecule)

61. Biologics (large molecule)

62. Gene Therapy

63. Medical Devices

64. In vitro Diagnostics

65. Combination Products

66. Generics

67. Due Diligence

68. Strategic medical writingAntonio 07Nov09www.drugstomarket.com

69. REGULATORY AFFAIRS CONSULTINGOverview of Therapeutic AreasA full range of Experience with many therapeutic areas, including:Oncology(gastric, colorectal, pancreatic, head and neck, hematological)Bones

70. Anti-infectives

71. Anti-inflammatory and Immunological diseases

72. Central Nervous System

73. Dermatology

74. Respiratory

75. Women’s healthAntonio 07Nov09www.drugstomarket.com

76. ANIMASCOPE EXPERTISEAnimascope has gathered the best expert capabilities to meet your experimental needs. Complementarity of competences and MULTIDISCIPLINARY EXPERTISE are core imperatives at AnimascopeAnimal and medical imaging, image processing, animal models, animal experimentation, experimental oncology, managementAntonio 07Nov09 Marc JANIER

77. Daniel CHRISTIAEN

78. Mimoun NEJJARI

79. Bassem HIBA

80. Antonio SERVADIOADVISORY BOARDSENIOR ADVISORSFrançoise BORSON CHAZOTHead of the Nuclear Medicine Unit, Hospital Neuro-Cardiologique, LyonJacques DEMONGEOTSpecialist of Medical Informatics, Biomatematics and Cognition Modeling, GrenobleJacques DESCOTESHead of the Poison Control and Toxicovigilance Centre, LyonGeorges HAOURProf. of Technology & Innovation Management at IMD, BaselPatrick HARDYDirector of Animal Science & Welfare at Merial R&D, LyonMarc JANIERHead of the Clinical Unit of Nuclear Medicine at the Edouard Herriot Hospital, LyonFounder of Animage in LyonOsman RATIBHead of the Clinical Unit of Nuclear Medicine at the Univ. Hospital, GenevaMohamed SLAOUISenior Toxicology Pathologist at Sanofi-Aventis, ParisAntonio 07Nov09

81. MEETINGS AND ROADSHOWSAnimascope participated in industry events by exhibiting, attending, or through distribution of company literature, including: WMIC 2008 (Nice-F)

82. EuroBio 2008 (Paris-F)

83. BioBusiness 2009 (Geneva-CH)

84. Molecular Imaging in Drug Dev. 2009 (London-UK)

85. Biosquare 2009 (Lyon-F)

86. BIO-Europe Spring 2009 (Milano-I)

87. CLARA 2009 (Archamps-F)

88. BioTrinity 2009 (Oxford-UK)

89. EuroPOLA 2009 (Paris-F)

90. ESMI 2009 (Barcelona-ES)

91. AFSTAL 2009 (Nantes-F)

92. Pharma Finance Zangani (Roma-I)

93. ECCP 2009 Eu Cancer Cluster (Toulouse-F)

94. ETS 2009 Eu Teratology Soc (Arles-F)

95. EUROBIO 2009 (Lille-F)

96. CLARA 2009 (Lyon-F)

97. BIO-Europe 2009 (Vienna-A)Antonio 07Nov09

98. ANIMASCOPE CONTACTAnimascope operates in Geneva, Lyon, St. Etienne (France)Contact:Antonio SERVADIO, Scientific Business Developmentwww.animascope.eua.servadio@animascope.euSkype: animascope.euMobile: +39 338 7949623www.animascope.euCurrent Animascope office located near GrenobleNew imaging facilitynear GenevaAntonio 07Nov09

99. IMAGINE YOUR PHENOTYPEAntonio 07Nov09